Effect of epirubicin combined with docetaxel or paclitaxel in the treatment of breast cancer
10.3969/j.issn.1005-1678.2017.07.101
- VernacularTitle:表柔比星联合多西他赛或紫杉醇治疗乳腺癌的效果分析
- Author:
Zhengxi WU
;
Minyu JU
;
Zhiye ZHANG
;
Jianfeng LI
;
Xueming XU
- Keywords:
epirubicin;
paclitaxel;
docetaxel;
breast cancer;
efficacy;
progn
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(7):251-252,254
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and prognosis of epirubicin combined with paclitaxel and epirubicin combined with docetaxel in the treatment of breast cancer.Methods Patients in the study group were treated with epirubicin and paclitaxel, while the control group was treated with epirubicin plus docetaxel.Results The two groups of breast cancer patients by the end of the treatment were valid for 5 years of follow-up, five year survival rate(86.67%)than the control group(68.89%), the study group the recurrence rate(4.44%)than in the control group(15.56%), the data had significant differences(P<0.05).Conclusion The epirubicin is conducive to breast cancer patients for better disease control effect and prognosis than star, paclitaxel combined with chemotherapy.
